SNS Financial Group’s Clovis Oncology, Inc. CLVS Stock Holding History

SNS Financial Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$12K	–	208
2022 Q3	$12K	Hold	10,000	–	–	﹤0.01%	189
2022 Q2	$18K	Hold	10,000	–	–	﹤0.01%	196
2022 Q1	$20K	Hold	10,000	–	–	﹤0.01%	220
2021 Q4	$27K	Hold	10,000	–	–	﹤0.01%	237
2021 Q3	$45K	Hold	10,000	–	–	0.01%	216
2021 Q2	$58K	Buy	+10,000	New	+$58.6K	0.01%	213

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

SNS Financial Group's CLVS Position: Q4 2022 in Review

SNS Financial Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 10,000 shares — an estimated $12K sold.

SNS Financial Group first reported a position in CLVS in Q2 2021 and held it in 6 quarters. The position peaked at $58K in Q2 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

SNS Financial Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
SNS Financial Group sold 10,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $12K.
SNS Financial Group first reported a position in Clovis Oncology, Inc. in Q2 2021 and held it in 6 quarters.
SNS Financial Group's Clovis Oncology, Inc. position peaked at $58K in Q2 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on SNS Financial Group's 13F filing for Q4 2022, filed 25 Jan 2023.